AstraZeneca PLC (NYSE:AZN) topped second-quarter profit expectations, with core earnings per share of $2.63 versus the $2.48 analysts expected. The firm reiterated its target of $80 billion in annual revenue by 2030. However, the quarter also brought fresh pipeline trouble: its rare disease drug Ultomiris missed its main goal in a late-stage trial for a rare blood vessel complication in adults, the latest in a string of setbacks that also includes an earlier heart drug trial failure and a breast cancer drug application that U.S. regulators rejected.
Why One Trial Miss Shook Confidence in the Whole Pipeline
AstraZeneca has built one of the richest valuations in European pharma on the assumption that its management reliably delivers successful late-stage trials. That assumption took a hit earlier this month when its heart drug Wainua failed a pivotal trial, sending shares down as much as 9% intraday before closing down 6.2%, the stock’s worst single day in more than two years, followed by another 3% drop the next day. Most analysts say the actual sales impact from Wainua’s failure is small, in the range of 2% to 4% of AstraZeneca PLC (NYSE:AZN)’s valuation, but the market reaction was roughly double that. It shows investors are questioning the broader pipeline, not just one drug. Even with the earnings beat, AstraZeneca’s stock is still down for the year.
This makes you question: is AstraZeneca’s run-of-trial disappointments a temporary rough patch or a sign its premium valuation is no longer justified?
The Bull Case
The core business is genuinely strong. Oncology revenue rose 15% with cancer drugs Tagrisso and Imfinzi leading the way, and an experimental gastric cancer drug, sonesitatug vedotin, met its main survival goal in a late-stage trial. AstraZeneca PLC (NYSE:AZN) also won EU approval for its breast cancer drug camizestrant, which it sells as Etcamah, and is more than halfway through a plan to launch 20 new medicines by 2030. CEO Pascal Soriot said, “I have never been more confident in the strength of our pipeline,” and most analysts, including Citi and Bank of America, still recommend buying the stock.
The Bear Case
The pipeline disappointments are piling up. A U.S. regulatory panel rejected camizestrant on trial design grounds back in May, even as the EU approved it. Revenue from China, AstraZeneca’s second biggest market, fell 13% due to generic competition and policy changes. AstraZeneca PLC (NYSE:AZN) is also adjusting its U.S. drug pricing in response to the Trump administration’s most favored nation policy, which ties some U.S. prices to what other wealthy countries pay, a shift that could pressure margins in its most lucrative market. Investor attention now turns to a lung cancer trial called AVANZAR, which analysts have flagged as the next major catalyst likely to determine whether the stock’s slump continues.
Insider Monkey’s Hedge Fund Data
Insider Monkey’s hedge fund database shows AstraZeneca had 56 hedge fund holders as of Q1 2026, up from 52 the quarter before. The dollar value hedge funds held rose from about $4.21 billion to $5.50 billion. Among pharma peers, Sanofi had 32 holders, flat from the quarter before; Novartis had 31, down from 35, and GSK had just 31, down sharply from 43. AstraZeneca PLC (NYSE:AZN) draws more hedge fund interest than all three.
Conclusion
AstraZeneca’s underlying business is still growing exactly as promised, but its recent run of trial failures means it now has less room for error. The market is judging every future readout more harshly than it used to. Overall, hedge funds are bullish on AstraZeneca PLC (NYSE:AZN).
While we acknowledge the risk and potential of AZN as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than AZN and that has 10,000% upside potential, check out our report about this cheapest AI stock.
READ NEXT: Hedge Funds Are Bullish on DXC Technology (DXC) and Blackstone Inc. (BX)’s Profit Jumped 26% on AI Bets but the Stock Barely Moved. Here’s Why.
Disclosure: None. This article is originally published at Insider Monkey.
Hedge Fund Resource Center